Table 3. Predictive factors of achieving LDL-C goal at Week 24 – multivariate analysis in patients randomized to alirocumab.
| Factor | Category | N | Number (%) of patients achieving LDL-C goal | Odds ratio (95% CI) | P-value |
|---|---|---|---|---|---|
| Distance to LDL-C goal† | <30 mg/dL (ref) | 832 | 745 (89.5) | — | <0.0001 |
| ≥30–<60 mg/dL | 801 | 675 (84.3) | 0.60 (0.44–0.81) | ||
| ≥60–<90 mg/dL | 370 | 251 (67.8) | 0.25 (0.18–0.35) | ||
| ≥90 mg/dL | 316 | 164 (51.9) | 0.13 (0.10–0.18) | ||
| Baseline free PCSK9 | <200 ng/mL (ref) | 424 | 301 (71.0) | — | 0.1449 |
| ≥200–<300 ng/mL | 815 | 655 (80.4) | 1.26 (0.94–1.68) | ||
| ≥300–<400 ng/mL | 573 | 465 (81.2) | 1.28 (0.93–1.76) | ||
| ≥400 ng/mL | 421 | 354 (84.1) | 1.51 (1.05–2.17) | ||
| Statin treatment | High-dose (ref) | 1310 | 1022 (78.0) | — | 0.2419 |
| Not high-dose | 1009 | 813 (80.6) | 1.14 (0.91–1.43) |
†Calculated as baseline LDL-C minus risk-based LDL-C goal.
Pool of FH I, COMBO II, and LONG TERM. Odds ratios and P-value calculated from a multivariate logistic regression. Patients with missing PCSK9 levels were excluded from the multivariate analysis. CI, confidence interval; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9.